BioSenic SA is a biotechnology company with extensive scientific and clinical experience in the field of orthopedics and regenerative therapies, specializing in the clinical development of therapies for bone and cartilage repair. BioSenic SA still holds stakes in its clinical assets ALLOB and JTA, but is now focusing on joint development with 4Moving Biotech of a GLP-1-based disease-modifying therapy for veterinary use, particularly for recovery after ligament surgery in dogs. BioSenic SA is also focusing on other potential new partnerships.

Employees

Sector

Pharmaceuticals

More about the company

28/10/25	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
03/10/25	BioSenic S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Market Cap	1.5M 1.74M 1.74M 1.42M 1.29M 2.42M 166M 2.43M 16.89M 6.49M 84.71M 6.55M 6.4M 268M	P/E 2023	-0.29x	P/E 2024	-0.28x
Enterprise Value	28.84M 33.47M 33.47M 27.31M 24.75M 46.43M 3.2B 46.67M 324M 125M 1.63B 126M 123M 5.14B	EV / Sales 2023	113x	EV / Sales 2024	286x
Free-Float	85.86%	Yield 2023 *	-	Yield 2024	-

28/10/25	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
03/10/25	BioSenic S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
29/09/25	Bone Therapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
28/10/24	BioSenic S.A. Announces Executive Changes	CI
30/09/24	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/09/24	Bone Therapeutics SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
17/09/24	BioSenic Deputy CEO Steps Down	MT
17/09/24	Véronique Pomi-Schneiter Step Down as BioSenic's Deputy CEO	CI
14/08/24	BioSenic Unit Secures European Patent for Multiple Sclerosis Treatment	MT
14/08/24	Medsenic, Subsidiary of Biosenic Receives the Intention to Grant Key European Patent from European Patent Office	CI
14/08/24	BioSenic Grants of A Key Patent by the Japan Patent Office to Expand Protection of the Arsenic Trioxide Platform	CI
18/07/24	Biosenic Releases New In-Depth Analysis of Its Positive Phase 2 Clinical Data for Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide Targeting Cgvhd	CI
05/07/24	BioSenic Seeks US Patent Extension for Sepsis Drug	MT

15/12	BioSenic : Report from Auditor on ESEF format 2024 Annual Report	PU
25/09/25	BioSenic : appoints CarKath SRL, represented by Mr Eric Halioua, as chairman of the board of directors	PU
30/08/25	BioSenic : provides an update on the preparation of the annual accounts and annual report for the financial year ending on 31 December 2024	PU
05/08/25	BioSenic : announces the homologation by the Enterprise Court of BioSenic's amicable agreements with five main creditors to restructure over €22 million of debt and appointment of two new independent directors	PU
02/07/25	BioSenic : announces partnership with 4Moving Biotech and secures its financing.	PU

08/05	BioSenic : Procuration pour l'actionnaire
08/05	BioSenic : Rapport annuel 2025
08/05	BioSenic : Communiqué de Presse - Convocation à l'Assemblée Générale Ordinaire
29/04	BioSenic : BIOS PR 2026 avril Denominator FR20260428
13/04	BioSenic : annonce l'émission de droits de souscription au bénéfice de membres du conseil d'administration

Bone Therapeutics SA Stock Euronext Bruxelles

Stocks

BOTHE

BE0974280126

Pharmaceuticals

Valuation : Bone Therapeutics SA

Latest news : Bone Therapeutics SA

Analysts' recommendations : Bone Therapeutics SA

Press Releases : Bone Therapeutics SA

News in other languages : Bone Therapeutics SA

Managers and Directors : Bone Therapeutics SA

Other Pharmaceuticals

Financials

Company Profile

Director	Title	Age	Since
Jean-Luc Vandebroek BRD	Director/Board Member	55	01/01/2022
Eric Halioua CHM	Chairman	-	01/09/2025
Virginie Miath BRD	Director/Board Member	-	29/01/2026

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.65%	-2.93%	+47.70%	+86.17%	994B
JOHNSON & JOHNSON	-0.29%	-3.51%	+49.15%	+62.35%	640B
ABBVIE INC.	+0.83%	+0.26%	+17.76%	+72.25%	454B
ROCHE HOLDING AG	-0.38%	-3.59%	+30.13%	+35.17%	337B
NOVARTIS AG	-0.09%	-13.54%	+13.34%	+24.95%	261B
ASTRAZENECA PLC	-0.43%	-2.48%	-0.73%	+9.58%	246B
AMGEN INC.	-1.34%	-13.70%	+36.53%	+44.96%	204B
NOVO NORDISK A/S	-3.44%	-7.51%	-20.63%	-59.44%	190B
GILEAD SCIENCES, INC.	-0.75%	-4.82%	+25.46%	+87.14%	178B
Average	-0.73%	-5.76%	+22.08%	+40.35%	389.42B
Weighted average by Cap.	-0.51%	-4.42%	+30.96%	+54.95%

	2023	2024
Net sales	336K 390K 390K 318K 288K 541K 37.26M 544K 3.78M 1.45M 18.95M 1.46M 1.43M 59.89M	102K 118K 118K 96.58K 87.54K 164K 11.31M 165K 1.15M 441K 5.75M 445K 435K 18.18M
Net income	-28.78M -33.4M -33.4M -27.25M -24.7M -46.34M -3.19B -46.57M -324M -124M -1.62B -125M -123M -5.13B	-4.77M -5.53M -5.53M -4.51M -4.09M -7.68M -529M -7.72M -53.62M -20.62M -269M -20.78M -20.33M -850M
Net Debt	28.04M 32.55M 32.55M 26.55M 24.07M 45.15M 3.11B 45.38M 315M 121M 1.58B 122M 120M 5B	27.34M 31.73M 31.73M 25.88M 23.46M 44.01M 3.03B 44.24M 307M 118M 1.54B 119M 117M 4.87B

End-of-day quote Euronext Bruxelles
-	-